NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hangzhou Yuannang Biotechnology Co., Ltd.

Hangzhou Yuannang Biotechnology Co., Ltd.

Private
HangzhouHealthcare & Life Scienceshttps://origobio.com.cn/

Last Round

Series A

Sep 11, 2025

Total Funding Raised

$14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hangzhou Yuannang Biotechnology Co., Ltd. is a biotechnology company that specializes in the research, development, production, and sales of musculoskeletal regenerative medical materials.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

bone adhesivebone glueregenerative medicineorthopedic repair materialsbone graftPRP preparation kitPRPbiodegradable materialsfracture fixationbiomaterialsdecellularized ECMmedical device manufacturerorthopedic surgeryinternal fixation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hangzhou Yuannang Biotechnology Co., Ltd. Comparables

Compare Hangzhou Yuannang Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Hangzhou Yuannang Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RevBio, Inc.
81%
Shanghai Rebone Biomaterials Co., Ltd.
79%
Biomimetic Innovations
78%

Hangzhou Yuannang Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 11, 2025
Early FundingAug 1, 2022
Early FundingOct 1, 2021

Hangzhou Yuannang Biotechnology Co., Ltd. Investors

Notable investors and investment history

Hangzhou Yuannang Biotechnology Co., Ltd. investors
InvestorRounds
Zheshang Venture CapitalEarly Funding, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 11, 2025

    $14M round led by Zheshang Venture Capital.

Hangzhou Yuannang Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hangzhou Yuannang Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hangzhou Yuannang Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Year Founded2022
Last FundingSep 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.